Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities (2017 - 2022)

Historic Other financing activities for UroGen Pharma (URGN) over the last 6 years, with Q3 2022 value amounting to $16000.0.

  • UroGen Pharma's Other financing activities fell 8620.69% to $16000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was $16000.0, marking a year-over-year decrease of 9422.38%. This contributed to the annual value of $160000.0 for FY2022, which is 1111.11% up from last year.
  • Per UroGen Pharma's latest filing, its Other financing activities stood at $16000.0 for Q3 2022, which was down 8620.69% from $55000.0 recorded in Q2 2022.
  • In the past 5 years, UroGen Pharma's Other financing activities registered a high of $202.7 million during Q3 2018, and its lowest value of $11000.0 during Q4 2020.
  • Moreover, its 4-year median value for Other financing activities was $89000.0 (2022), whereas its average is $52.7 million.
  • In the last 5 years, UroGen Pharma's Other financing activities soared by 5090025.06% in 2018 and then plummeted by 8620.69% in 2022.
  • Quarter analysis of 4 years shows UroGen Pharma's Other financing activities stood at $202.7 million in 2018, then crashed by 99.99% to $11000.0 in 2020, then skyrocketed by 54.55% to $17000.0 in 2021, then decreased by 5.88% to $16000.0 in 2022.
  • Its Other financing activities was $16000.0 in Q3 2022, compared to $55000.0 in Q2 2022 and $89000.0 in Q1 2022.